` IKNA (Ikena Oncology Inc) vs S&P 500 Comparison - Alpha Spread

IKNA
vs
S&P 500

Over the past 12 months, IKNA has underperformed S&P 500, delivering a return of -14% compared to the S&P 500's +14% growth.

Stocks Performance
IKNA vs S&P 500

Loading
IKNA
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
IKNA vs S&P 500

Loading
IKNA
S&P 500
Difference
www.alphaspread.com

Performance By Year
IKNA vs S&P 500

Loading
IKNA
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Ikena Oncology Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Ikena Oncology Inc
Glance View

Market Cap
2.1B USD
Industry
Pharmaceuticals

Ikena Oncology, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. The company intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The firm is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. The company also has early stage discovery programs in targeted oncology in the RAS pathway.

IKNA Intrinsic Value
Not Available
Back to Top